Aligos announces FDA cleared IND for Phase 1 DDI study of ALG-000184

Aligos Therapeutics (ALGS) announced that the U.S. Food and Drug Administration, FDA, has cleared the Company’s Investigational New Drug, IND, for a Phase 1 Drug-Drug Interaction, DDI, study of ALG-000184, a capsid assembly modulator, CAM-E, for the treatment of Chronic Hepatitis B, CHB. “The acceptance of our third U.S. IND is an important milestone for Aligos,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “This IND clearance allows us to begin the next stages of our clinical development for ALG-000184, including the advancement of the compound into Phase 2 clinical trials. ALG-000184 is the first novel, oral drug candidate for the treatment of HBV infection that can inhibit multiple components of the viral lifecycle, leading to more complete suppression of the virus compared to other therapeutic modalities.”